These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30762768)

  • 1. Intracoronary administration of nicorandil-induced cardiac arrest during primary percutaneous coronary intervention: A case report.
    Wei SJ; Luan FY; He DY; Xu F; Chen YG
    Medicine (Baltimore); 2019 Feb; 98(7):e14473. PubMed ID: 30762768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect on myocardial perfusion and clinical outcome of intracoronary nicorandil injection prior to percutaneous coronary intervention in ST-segment elevation myocardial infarction].
    Wang ZQ; Chen MX; Liu DL; Zheng WX; Cao XZ; Chen H; Huang MF; Luo ZR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jan; 45(1):26-33. PubMed ID: 28100342
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Geng N; Ren L; Xu L; Zou D; Pang W
    BMC Cardiovasc Disord; 2021 Oct; 21(1):488. PubMed ID: 34629058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
    Qi Q; Niu J; Chen T; Yin H; Wang T; Jiang Z
    Med Sci Monit; 2018 May; 24():2767-2776. PubMed ID: 29726480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
    Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
    BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Early Intracoronary Administration of Nicorandil During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction.
    Feng C; Liu Y; Wang L; Niu D; Han B
    Heart Lung Circ; 2019 Jun; 28(6):858-865. PubMed ID: 29891250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention.
    Wang S; Duan Y; Feng X; Liu L; Shi Z; Wang B; Xia C; Man W; Wang H; Zhao Z; Sun D
    Anatol J Cardiol; 2019 Mar; 21(3):163-171. PubMed ID: 30821716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Gupta H; Parihar S; Tripathi VD
    Cureus; 2022 May; 14(5):e25349. PubMed ID: 35761910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactically injection of Nicorandil to reduce no-reflow phenomenon during PCI in acute STEMI patients: Protocol of a double-blinded, randomized, placebo-controlled trial.
    An S; Huang H; Wang H; Jiang Y
    Medicine (Baltimore); 2021 Apr; 100(15):e25500. PubMed ID: 33847663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients.
    Yang L; Mu L; Sun L; Qi F; Guo R
    Minerva Cardioangiol; 2017 Apr; 65(2):111-118. PubMed ID: 27249789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory cardiac arrest caused by type I Kounis syndrome treated with adrenaline and nicorandil: A case report.
    Ichinomiya T; Sekino M; Toba M; Yokoyama A; Iwasaki N; Kasai Y; Araki H; Yano R; Matsumoto S; Kurobe M; Sasaki R; Hara T
    Medicine (Baltimore); 2023 Aug; 102(32):e34535. PubMed ID: 37565887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events associated with nicorandil administration prior to primary percutaneous coronary intervention in patients with acute ST-segment elevated myocardial infarction: a systematic review and meta-analysis.
    Li J; Xu X; Zhou X; Dai J; Ma L; Chen C; Li X; Mao W
    Expert Opin Drug Saf; 2019 Jun; 18(6):537-547. PubMed ID: 31117845
    [No Abstract]   [Full Text] [Related]  

  • 13. One-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Occlusion Treated by Primary Percutaneous Coronary Intervention.
    Liu HW; Han YL; Jin QM; Wang XZ; Ma YY; Wang G; Wang B; Xu K; Li Y; Chen SL
    Chin Med J (Engl); 2018 Jun; 131(12):1412-1419. PubMed ID: 29893357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil.
    Matsuo H; Watanabe S; Watanabe T; Warita S; Kojima T; Hirose T; Iwama M; Ono K; Takahashi H; Segawa T; Minatoguchi S; Fujiwara H
    Am Heart J; 2007 Nov; 154(5):994.e1-6. PubMed ID: 17967610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No-reflow phenomenon during percutaneous coronary intervention in a patient with polycythemia vera: A case report.
    Oktaviono YH; Hutomo SA; Al-Farabi MJ
    Medicine (Baltimore); 2020 Feb; 99(9):e19288. PubMed ID: 32118741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina.
    Hwang J; Lee HC; Kim BW; Yang MJ; Park JS; Park JH; Lee HW; Oh J; Choi JH; Cha KS; Hong TJ; Song S; Kim SP
    J Cardiol; 2013 Aug; 62(2):77-81. PubMed ID: 23731922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study.
    Ito N; Nanto S; Doi Y; Kurozumi Y; Natsukawa T; Shibata H; Morita M; Kawata A; Tsuruoka A; Sawano H; Okada K; Sakata Y; Kai T; Hayashi T
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):279-87. PubMed ID: 23722418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cardiac parameters after the administration of nicorandil before primary percutaneous coronary intervention.
    Ilyas M; Noor M; Haroon S; Farhat K; Ali S; Wahid M
    J Pak Med Assoc; 2024 May; 74(5):917-921. PubMed ID: 38783440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracoronary administration of nicorandil for the treatment of spontaneous microvascular spasm with ST segment elevation.
    Satoshi K; Ichiro I; Takuji K; Masaharu I; Yuji S; Kenji N; Suji N; Takashi U; Masashi Y
    Circ J; 2004 Mar; 68(3):267-9. PubMed ID: 14993785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI.
    Kostic J; Djordjevic-Dikic A; Dobric M; Milasinovic D; Nedeljkovic M; Stojkovic S; Stepanovic J; Tesic M; Trifunovic Z; Zamaklar-Tifunovic D; Radosavljevic-Radovanovic M; Ostojic M; Beleslin B
    Cardiovasc Ultrasound; 2015 May; 13():26. PubMed ID: 26012474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.